Effect of prostaglandin E1 on graft function of kidneys from living related donors.
Prostaglandin E1 (PGE1) was used in renal transplant recipients with living related donors. The drug was given intravenously from day 1 to day 7 after transplantation at a dose of 40 microg/kg twice a day. A total of 45 patients were studied divided into two groups: 25 patients were treated with PGE1 (group B) and the remaining 20 patients did not receive the drug (group A). In group B, 24-h creatinine clearance (Ccr) was 66 +/- 12.8 ml/min compared with 40.3 +/- 13.4 ml/min in group A on the fifth postoperative day (P < 0.05). Urinary levels of N-acetyl-beta-D-glucosaminidase (NAG) and serum levels of platelet factor 4 (PF4) in group B were significantly lower than in group A. On the fourth postoperative day, the urinary excretion of thromboxan B2 (TxB2) in group A was higher than in group B, but not significantly (5.1 +/- 3.0 ng/day and 2.8 +/- 1.1 ng/day, respectively). Acute rejection occurred in four patients in group B and in 10 patients (40%) in group A. The percentage of Leu2a-positive lymphocytes in group B was higher than in group A. We conclude that postoperative administration of PGE1 improves graft function in kidneys from living related donors.
Ohsaki
S
S
Third Department of Surgery, Tokyo Women's Medical College, 8-1 Kawada-cho Sinjuku-ku, Tokyo, Japan.
Teraoka
S
S
Tojimbara
T
T
Takahasi
K
K
Toma
H
H
Agishi
T
T
Ota
K
K
D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D001787:Blood Group Incompatibility; D003404:Creatinine / Q000097:blood; D005190:Family; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology; D006650:Histocompatibility Testing; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D010978:Platelet Factor 4 / Q000378:metabolism; D013929:Thromboxane B2 / Q000652:urine
D010978:Platelet Factor 4; D013929:Thromboxane B2; D003404:Creatinine; D000527:Alprostadil